References
- Irwin JP, Ronald PE. Butorphanol. Drug Alcohol Depen 1985;14:325–338
- http://www.drugs.com/ppa/butorphanol-tartrate.html
- Gadwal P, Rudrawal P. A review on osmotically regulated devices. Int J Pharm Life Sci 2010;1:302–312
- Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999;51:135–158
- Cheng-Chung T. Identification and localization of five CYP2Cs in murine extrahepatic tissues and their metabolism of arachidonic acid to regio and stereo selective products. Pharmacol Exp Ther 2001;299:39–47
- Gavhane YN, Yadav AV. Loss of orally administered drugs in GI tract. Saudi Pharm J 2012;20:331–344
- Kangale P, Lohray BB, Misra A, et al. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. AAPS Pharm SciTech 2007;8:E13–E19
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. “Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers” 2005. Guidance for industry by USFDA. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf [last accessed 21 Sep 2011]
- Philip OA, James ED, William GT. Handbook of clinical data. In: Analgesic and anti-inflammatory drugs. 10th ed. USA: McGraw-Hill; 2001:3–54
- Gilbert MM, Sanzari NP, Losada M, Caruso FS. Double-blind oral analgesic study of butorphanol in musculoskeletal pain: a comparison with codeine and placebo. J Int Med Res 1978;6:14–23
- Pittman KA, Smyth RD, Mayol RF. Serum levels of butorphanol by radioimmunoassay. J Pharm Sci 1980;69:160–163
- Langenbucher F, Mysicka J. In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations. Br J Clin Pharm 1985;19:151S–162S
- Mehvar R. Pharmacokinetic-based design and modification of dosage regimens. Am J Pharm Educ 1998;62:189–195
- Bharate SS, Bharateb SB, Bajajc AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients, a comprehensive review. J Excipients Food Chem 2010;1:3–26
- US Department of Health and Human Services Food and Drug Administration. Inactive ingredient search for approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm [last accessed 15 Sep 2011]
- European Medical Agency. “Guideline on quality of oral modified release products” EMA/492713/2012
- Meyer RJ, Hussain AS. FDA’s ACPS meeting, awareness topic: mitigating the risks of ethanol induced dose dumping from oral sustained/controlled release dosage forms. October 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4187B1_01_08-Alcohol-Induced.pdf [last accessed 25 Sep 2011]
- Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–133
- Vyas SP, Khar RK. Controlled drug delivery, concepts and advances. 1st ed. Delhi: Vallabh Prakashan; 2002:477–502
- Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975;64:1987–1991
- Nikam PH, Kareparamban JA, Jadhav AP, Kadam VJ. Osmotic pump: a reliable drug delivery system. RJPBCS 2012;3:478–493
- Mahalaxmi R, Sastri P, Ravikumar, et al. Enhancement of dissolution of glipizide from controlled porosity osmotic pump using a wicking agent and a solubilizing agent. Int J Pharm Tech Res 2009;1:705–711
- Kumaravelrajan R, Narayanan N, Suba V. Development and evaluation of controlled porosity osmotic pump for Nifedipine and Metoprolol combination. Lipids Health Dis 2011;10:51--63
- Rathore GS, Gupta RN. Formulation development and evaluation of controlled porosity osmotic pump delivery system for oral delivery of atenolol. Asian J Pharm 2012;6:151–160
- Patel A, Mehta T, Patel M, et al. Recent patent in controlled porosity osmotic pump. Recent Pat Drug Deliv Formul 2013;7:66–72
- Ahmed A, Mina IT, Ahmed AAE. Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets. AAPS Pharm Sci Tech 2011;12:485–495